S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
This 11% Dividend Stock Has 11%+ Upside, Too
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
This 11% Dividend Stock Has 11%+ Upside, Too
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
This 11% Dividend Stock Has 11%+ Upside, Too
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
MarketBeat Week in Review – 1/30 - 2/3
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
State of the Union: Biden sees economic glow, GOP sees gloom
Why a new Alzheimer's drug is having a slow US debut
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Sri Lanka marks independence anniversary amid economic woes
Tesla hikes price of Model Y after US alters tax credit rule
“Future Fuel” will unleash $11 trillion wave of wealth (Ad)
Disney World unions vote down offer covering 45,000 workers
This 11% Dividend Stock Has 11%+ Upside, Too
NASDAQ:GH

Guardant Health - GH Stock Forecast, Price & News

$31.94
-0.45 (-1.39%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$30.59
$32.52
50-Day Range
$25.44
$53.81
52-Week Range
$24.63
$78.34
Volume
1.85 million shs
Average Volume
1.59 million shs
Market Capitalization
$3.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$90.39

Guardant Health MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.94 Rating Score
Upside/​Downside
183.0% Upside
$90.39 Price Target
Short Interest
Bearish
5.74% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.95
Upright™ Environmental Score
News Sentiment
0.79mentions of Guardant Health in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$162,094 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($6.46) to ($5.19) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.43 out of 5 stars

Medical Sector

167th out of 1,028 stocks

Medical Laboratories Industry

4th out of 25 stocks

GH stock logo

About Guardant Health (NASDAQ:GH) Stock

Guardant Health, Inc. is a precision oncology company engaged in the treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. Its solutions include treatment selection, recurrence detection, and early detection. The company was founded by Helmy Eltoukhy, AmirAli H. Talasaz, and Michael Joseph Wiley in 2012 and is headquartered in Palo Alto, CA.

Receive GH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.

GH Stock News Headlines

A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
GH.OQ - | Stock Price & Latest News | Reuters
Guardant Health Looks Downright Sickly
Guardant Health Recent Insider Activity
Guardant Health Unusual Options Activity
Guardant: Saving Lives One Blood Test At A Time
See More Headlines
Receive GH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Guardant Health and its competitors with MarketBeat's FREE daily newsletter.

GH Company Calendar

Last Earnings
11/04/2021
Today
2/04/2023
Next Earnings (Confirmed)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Employees
1,373
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$90.39
High Stock Price Forecast
$165.00
Low Stock Price Forecast
$36.00
Forecasted Upside/Downside
+183.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.94
Research Coverage
16 Analysts

Profitability

Net Income
$-405,670,000.00
Net Margins
-140.58%
Pretax Margin
-136.14%

Debt

Sales & Book Value

Annual Sales
$373.65 million
Book Value
$6.34 per share

Miscellaneous

Free Float
96,392,000
Market Cap
$3.27 billion
Optionable
Not Optionable
Beta
0.86

Key Executives

  • Helmy EltoukhyHelmy Eltoukhy
    Chairman & Co-Chief Executive Officer
  • AmirAli H. TalasazAmirAli H. Talasaz
    Co-Chief Executive Officer & Director
  • Andrew Ament
    Senior Vice President-Operations
  • Michael Bell
    Chief Financial & Accounting Officer
  • Darya Chudova
    Senior Vice President-Technology













GH Stock - Frequently Asked Questions

Should I buy or sell Guardant Health stock right now?

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Guardant Health in the last twelve months. There are currently 1 hold rating and 15 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" GH shares.
View GH analyst ratings
or view top-rated stocks.

What is Guardant Health's stock price forecast for 2023?

16 brokers have issued twelve-month price objectives for Guardant Health's stock. Their GH share price forecasts range from $36.00 to $165.00. On average, they expect the company's stock price to reach $90.39 in the next twelve months. This suggests a possible upside of 183.0% from the stock's current price.
View analysts price targets for GH
or view top-rated stocks among Wall Street analysts.

How have GH shares performed in 2023?

Guardant Health's stock was trading at $27.20 at the beginning of 2023. Since then, GH stock has increased by 17.4% and is now trading at $31.94.
View the best growth stocks for 2023 here
.

When is Guardant Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our GH earnings forecast
.

How can I listen to Guardant Health's earnings call?

Guardant Health will be holding an earnings conference call on Thursday, February 23rd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

How were Guardant Health's earnings last quarter?

Guardant Health, Inc. (NASDAQ:GH) posted its quarterly earnings results on Thursday, November, 4th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.90) by $0.16. The company had revenue of $94.80 million for the quarter, compared to the consensus estimate of $92.59 million. Guardant Health had a negative net margin of 140.58% and a negative trailing twelve-month return on equity of 145.58%. The business's revenue for the quarter was up 26.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.78) EPS.

What guidance has Guardant Health issued on next quarter's earnings?

Guardant Health issued an update on its FY 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $447.00 million-$450.00 million, compared to the consensus revenue estimate of $445.24 million.

What is Helmy Eltoukhy's approval rating as Guardant Health's CEO?

52 employees have rated Guardant Health Chief Executive Officer Helmy Eltoukhy on Glassdoor.com. Helmy Eltoukhy has an approval rating of 95% among the company's employees. This puts Helmy Eltoukhy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Guardant Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Guardant Health investors own include NVIDIA (NVDA), Trade Desk (TTD), Block (SQ), Alibaba Group (BABA), PayPal (PYPL), Shopify (SHOP), Okta (OKTA), Alteryx (AYX), Roku (ROKU) and Twilio (TWLO).

When did Guardant Health IPO?

(GH) raised $200 million in an initial public offering on Thursday, October 4th 2018. The company issued 12,500,000 shares at $15.00-$17.00 per share. J.P. Morgan and BofA Merrill Lynch acted as the underwriters for the IPO and Cowen, Leerink Partners and William Blair were co-managers.

What is Guardant Health's stock symbol?

Guardant Health trades on the NASDAQ under the ticker symbol "GH."

Who are Guardant Health's major shareholders?

Guardant Health's stock is owned by a number of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (0.49%), New York State Common Retirement Fund (0.24%), Sicart Associates LLC (0.10%), Sumitomo Mitsui Trust Holdings Inc. (0.08%), Simplex Trading LLC (0.00%) and SWS Partners (0.04%). Insiders that own company stock include Amelia Merrill, Amirali Talasaz, Bluebird (Cayman) Ltd Svf, Derek A Bertocci, Helmy Eltoukhy, Ian T Clark, Kumud Kalia, Michael J Wiley, Samir Kaul, Stanley J Meresman and Stanley J Meresman.
View institutional ownership trends
.

How do I buy shares of Guardant Health?

Shares of GH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Guardant Health's stock price today?

One share of GH stock can currently be purchased for approximately $31.94.

How much money does Guardant Health make?

Guardant Health (NASDAQ:GH) has a market capitalization of $3.27 billion and generates $373.65 million in revenue each year. The company earns $-405,670,000.00 in net income (profit) each year or ($5.93) on an earnings per share basis.

How many employees does Guardant Health have?

The company employs 1,373 workers across the globe.

How can I contact Guardant Health?

Guardant Health's mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The official website for the company is www.guardanthealth.com. The company can be reached via phone at (855) 698-8887, via email at investors@guardanthealth.com, or via fax at 888-974-4258.

This page (NASDAQ:GH) was last updated on 2/5/2023 by MarketBeat.com Staff